Stem definition | Drug id | CAS RN |
---|---|---|
1647 | 51-75-2 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
March 15, 1949 | FDA | RECORDATI RARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pruritus | 438.87 | 54.54 | 80 | 1761 | 3739 | 56286487 |
Application site pain | 360.00 | 54.54 | 68 | 1773 | 3852 | 56286374 |
Application site erythema | 324.67 | 54.54 | 64 | 1777 | 4536 | 56285690 |
Application site discolouration | 234.10 | 54.54 | 37 | 1804 | 715 | 56289511 |
Application site irritation | 205.01 | 54.54 | 37 | 1804 | 1615 | 56288611 |
Skin discolouration | 160.91 | 54.54 | 55 | 1786 | 34301 | 56255925 |
Pruritus | 153.45 | 54.54 | 106 | 1735 | 316517 | 55973709 |
Skin irritation | 144.81 | 54.54 | 37 | 1804 | 8418 | 56281808 |
Application site vesicles | 114.58 | 54.54 | 22 | 1819 | 1343 | 56288883 |
Erythema | 114.33 | 54.54 | 68 | 1773 | 155871 | 56134355 |
Application site dryness | 103.31 | 54.54 | 15 | 1826 | 158 | 56290068 |
Therapy non-responder | 100.62 | 54.54 | 46 | 1795 | 61309 | 56228917 |
Skin burning sensation | 81.49 | 54.54 | 25 | 1816 | 11006 | 56279220 |
Application site discharge | 80.60 | 54.54 | 12 | 1829 | 152 | 56290074 |
Application site exfoliation | 71.17 | 54.54 | 12 | 1829 | 348 | 56289878 |
Application site inflammation | 63.66 | 54.54 | 11 | 1830 | 370 | 56289856 |
Skin hyperpigmentation | 60.90 | 54.54 | 17 | 1824 | 5380 | 56284846 |
Cutaneous T-cell lymphoma | 55.12 | 54.54 | 12 | 1829 | 1363 | 56288863 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pruritus | 479.75 | 66.97 | 81 | 1892 | 1229 | 31694142 |
Application site erythema | 421.15 | 66.97 | 78 | 1895 | 2051 | 31693320 |
Application site pain | 364.55 | 66.97 | 67 | 1906 | 1682 | 31693689 |
Pruritus | 208.10 | 66.97 | 116 | 1857 | 125051 | 31570320 |
Application site irritation | 188.80 | 66.97 | 33 | 1940 | 612 | 31694759 |
Skin irritation | 182.44 | 66.97 | 45 | 1928 | 4652 | 31690719 |
Application site vesicles | 173.70 | 66.97 | 30 | 1943 | 517 | 31694854 |
Therapy non-responder | 143.98 | 66.97 | 60 | 1913 | 33751 | 31661620 |
Application site discolouration | 125.31 | 66.97 | 20 | 1953 | 206 | 31695165 |
Erythema | 120.76 | 66.97 | 70 | 1903 | 80335 | 31615036 |
Cutaneous T-cell lymphoma | 110.88 | 66.97 | 24 | 1949 | 1387 | 31693984 |
Skin burning sensation | 109.87 | 66.97 | 29 | 1944 | 3910 | 31691461 |
Application site discharge | 95.30 | 66.97 | 15 | 1958 | 140 | 31695231 |
Blister | 91.81 | 66.97 | 38 | 1935 | 20898 | 31674473 |
Application site burn | 83.27 | 66.97 | 14 | 1959 | 203 | 31695168 |
Skin discolouration | 83.17 | 66.97 | 33 | 1940 | 16274 | 31679097 |
Application site exfoliation | 77.78 | 66.97 | 12 | 1961 | 97 | 31695274 |
Second primary malignancy | 76.72 | 66.97 | 25 | 1948 | 7007 | 31688364 |
Application site swelling | 75.16 | 66.97 | 13 | 1960 | 225 | 31695146 |
Application site erosion | 73.60 | 66.97 | 11 | 1962 | 70 | 31695301 |
Disease progression | 67.54 | 66.97 | 51 | 1922 | 90413 | 31604958 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pruritus | 907.70 | 48.13 | 158 | 3588 | 3443 | 70921255 |
Application site erythema | 741.64 | 48.13 | 139 | 3607 | 4622 | 70920076 |
Application site pain | 688.59 | 48.13 | 129 | 3617 | 4273 | 70920425 |
Application site irritation | 400.37 | 48.13 | 70 | 3676 | 1547 | 70923151 |
Application site discolouration | 338.09 | 48.13 | 54 | 3692 | 670 | 70924028 |
Pruritus | 333.79 | 48.13 | 213 | 3533 | 345347 | 70579351 |
Skin irritation | 303.64 | 48.13 | 76 | 3670 | 9833 | 70914865 |
Application site vesicles | 272.12 | 48.13 | 49 | 3697 | 1284 | 70923414 |
Therapy non-responder | 238.65 | 48.13 | 104 | 3642 | 76811 | 70847887 |
Skin discolouration | 219.06 | 48.13 | 80 | 3666 | 37245 | 70887453 |
Erythema | 216.75 | 48.13 | 133 | 3613 | 199430 | 70725268 |
Skin burning sensation | 185.17 | 48.13 | 53 | 3693 | 11373 | 70913325 |
Application site discharge | 173.22 | 48.13 | 27 | 3719 | 282 | 70924416 |
Application site dryness | 162.80 | 48.13 | 24 | 3722 | 166 | 70924532 |
Application site exfoliation | 125.32 | 48.13 | 21 | 3725 | 355 | 70924343 |
Cutaneous T-cell lymphoma | 121.64 | 48.13 | 28 | 3718 | 2525 | 70922173 |
Application site swelling | 119.23 | 48.13 | 22 | 3724 | 660 | 70924038 |
Disease progression | 105.93 | 48.13 | 78 | 3668 | 156594 | 70768104 |
Application site erosion | 99.33 | 48.13 | 16 | 3730 | 209 | 70924489 |
Skin hyperpigmentation | 99.18 | 48.13 | 29 | 3717 | 6686 | 70918012 |
Application site burn | 96.78 | 48.13 | 19 | 3727 | 797 | 70923901 |
Blister | 96.12 | 48.13 | 62 | 3684 | 100464 | 70824234 |
Dry skin | 94.70 | 48.13 | 50 | 3696 | 55881 | 70868817 |
Application site inflammation | 94.24 | 48.13 | 17 | 3729 | 448 | 70924250 |
Application site rash | 90.21 | 48.13 | 21 | 3725 | 1988 | 70922710 |
Dermatitis | 89.74 | 48.13 | 35 | 3711 | 19382 | 70905316 |
Application site reaction | 74.67 | 48.13 | 15 | 3731 | 708 | 70923990 |
Skin exfoliation | 72.58 | 48.13 | 40 | 3706 | 48586 | 70876112 |
Application site scab | 71.93 | 48.13 | 12 | 3734 | 197 | 70924501 |
Second primary malignancy | 61.97 | 48.13 | 24 | 3722 | 13027 | 70911671 |
Application site haemorrhage | 55.38 | 48.13 | 13 | 3733 | 1275 | 70923423 |
Scab | 54.22 | 48.13 | 20 | 3726 | 9498 | 70915200 |
Cutaneous T-cell lymphoma recurrent | 53.92 | 48.13 | 8 | 3738 | 58 | 70924640 |
Lymphomatoid papulosis | 53.20 | 48.13 | 10 | 3736 | 332 | 70924366 |
None
Source | Code | Description |
---|---|---|
ATC | L01AA05 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrogen mustard analogues |
FDA MoA | N0000000236 | Alkylating Activity |
FDA EPC | N0000175558 | Alkylating Drug |
MeSH PA | D000477 | Alkylating Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018906 | Antineoplastic Agents, Alkylating |
MeSH PA | D002619 | Chemical Warfare Agents |
MeSH PA | D007509 | Irritants |
MeSH PA | D009676 | Noxae |
MeSH PA | D011042 | Poisons |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic lymphoid leukemia, disease | indication | 92814006 | |
Chronic myeloid leukemia | indication | 92818009 | DOID:8552 |
Polycythemia vera | indication | 109992005 | |
Hodgkin's disease | indication | 118599009 | |
Non-Hodgkin's lymphoma | indication | 118601006 | |
Mycosis fungoides | indication | 118618005 | |
Malignant tumor of lung | indication | 363358000 | |
Primary cutaneous T-cell lymphoma | indication | 400122007 | |
Pericardial Malignant Effusions | indication | ||
Peritoneal Malignant Effusions | indication | ||
Pleural Malignant Effusions | indication | ||
Amyloidosis | contraindication | 17602002 | DOID:9120 |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Acute infectious disease | contraindication | 63171007 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Secondary malignant neoplasm of bone marrow | contraindication | 94217008 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Granulocytopenic disorder | contraindication | 417672002 | |
Chemotherapy-Induced Hyperuricemia | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 5.7 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | 8501819 | March 7, 2026 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
EQ 0.016% BASE | VALCHLOR | HELSINN | N202317 | Aug. 23, 2013 | RX | GEL | TOPICAL | 7872050 | July 8, 2029 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
None
None
ID | Source |
---|---|
4019808 | VUID |
N0000147897 | NUI |
D04872 | KEGG_DRUG |
4017994 | VANDF |
4019808 | VANDF |
C0025033 | UMLSCUI |
CHEBI:28925 | CHEBI |
CHEMBL427 | ChEMBL_ID |
DB00888 | DRUGBANK_ID |
CHEMBL1201001 | ChEMBL_ID |
D008466 | MESH_DESCRIPTOR_UI |
4033 | PUBCHEM_CID |
586 | INN_ID |
7218 | IUPHAR_LIGAND_ID |
55-86-7 | SECONDARY_CAS_RN |
50D9XSG0VR | UNII |
155036 | RXNORM |
1972 | MMSL |
29634 | MMSL |
5028 | MMSL |
d01339 | MMSL |
002630 | NDDF |
004816 | NDDF |
29156002 | SNOMEDCT_US |
372692002 | SNOMEDCT_US |
387071000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
VALCHLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69639-120 | GEL | 0.01 g | TOPICAL | NDA | 28 sections |
VALCHLOR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69639-120 | GEL | 0.01 g | TOPICAL | NDA | 28 sections |